Research programme: cognition disorder therapeutics - Cortice Biosciences

Drug Profile

Research programme: cognition disorder therapeutics - Cortice Biosciences

Alternative Names: B1-ADR partial agonist- Cortice Biosciences; CRT 001; Xalmoterol fumarate - Cortice Biosciences

Latest Information Update: 13 Jul 2015

Price : $50

At a glance

  • Originator Stanford University
  • Developer Cortice Biosciences
  • Class Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Down syndrome

Most Recent Events

  • 09 Jul 2015 Cortice Biosciences receives patent allowance for CRT 001 in USA
  • 12 Nov 2014 Pharmacodynamic data from preclinical studies in Alzheimer's disease released by Cortice Biosciences
  • 31 Jul 2014 Preclinical trials in Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top